Navigation Links
ACell Expands Indiana Manufacturing Facility to Support Growth
Date:10/25/2013

COLUMBIA, Md., Oct. 25, 2013 /PRNewswire/ -- ACell, Inc., a leading regenerative medicine company focused on the development, manufacturing and commercialization of surgical and wound management products, today announced that it has broken ground on the expansion of its manufacturing facility in Lafayette, Indiana to support the Company's current and anticipated growth.

The 14,000 square-foot addition to the current building will increase scalability and efficiency of ACell's day-to-day operations and is expected to be completed in late 2014. With the expansion, the total manufacturing space will exceed 42,000 square feet.

"The significant growth of our business driven by continued physician adoption of MatriStem® has driven us to expand capacity at our Lafayette facility by roughly 50 percent," said Rodney Bosley, ACell President and Chief Operating Officer. "Our Indiana facility is currently capable of producing all of our 510(k) cleared products from raw material processing through final packaging. This expansion will provide us with additional end-to-end manufacturing capabilities that we believe will support our growth for several years to come." 

ACell manufactures its MatriStem products in facilities located in Lafayette, Indiana and Columbia, Maryland using a complex and highly specialized process, requiring precision and expertise to address various technical, engineering and regulatory challenges.  The Lafayette facility processes all of the material used in MatriStem products and manufactures the majority of ACell's products.

"As an integral part of the Lafayette community, ACell offers an opportunity to help stimulate the local economy, and we are proud to support the Company as they expand their facility with the goal of transforming the standard of medical care and improving the quality of life of patients who are treated with their devices," said City of Lafayette Mayor Tony Roswarski.

ACell, Inc. offers the next generation of regenerative medicine through the development and commercialization of unique extracellular matrix products to repair and remodel damaged tissues in a broad range of applications. Its patented MatriStem ECM medical devices maintain and support a healing environment through constructive remodeling and are available in particle and sheet forms for the treatment of acute wounds and use in various surgical procedures. For more information, visit www.acell.com.

About ACell, Inc.
ACell, Inc. is a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products. Its medical devices are cleared for a variety of indications and are marketed under the brand name "MatriStem." A privately held company, ACell produces MatriStem at its full scale manufacturing facilities in Columbia, MD and Lafayette, IN, and markets its products to physicians in the U.S. through a national direct sales force. For more information, call (800) 826-2926 or visit www.acell.com.

About MatriStem®
MatriStem Products are porcine-derived extracellular matrix (ECM), essential structures that maintain and support a healing environment through constructive tissue remodeling. MatriStem contains the basement membrane of porcine urinary bladder tissue, or urinary bladder matrix (UBM).  UBM is a layer of tissue that is a critical component of constructive tissue remodeling. It provides MatriStem with several distinguishable characteristics, including the ability to facilitate the body's own regenerative capabilities and help restore normal site-appropriate tissue while avoiding scar tissue formation; the ability to be used "off-the-shelf" and stored at room temperature; and superior ease-of-use. MatriStem products are indicated for use in a wide range of regenerative and tissue repair applications and come in a range of sizes and thicknesses. It is the only ECM of its kind available in powder form. It has been cleared for use in general surgery, gynecological surgery and a wide range of wounds, including diabetic foot ulcers, venous leg ulcers, pressure, surgical, and tunneled wounds. Refer to the Instructions For Use supplied with each device for indications, contraindications, and precautions. All MatriStem devices are made in the USA. 

Contacts: 

Jon Werner
Director of Marketing
(410) 715-1700

Kirsten Thomas (media)
The Ruth Group 
646-536-7014 
kthomas@theruthgroup.com 


'/>"/>
SOURCE ACell, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Blood-Based Circulating Microvesicles (cMV) Data to be Presented at the 2013 International Society for Extracellular Vesicles (ISEV)
2. Unique Extracellular Matrix Used in Patient Successfully Treated for Flesh Eating Bacteria
3. UV Flu Technologies Expands Its International Footprint
4. Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology
5. Ansell Limited Expands Korean Presence
6. Premier Research Expands Salt Lake City and Phoenix Testing Facilities Adding 50% Capacity
7. Groundbreaking National Program to Reverse Obesity Expands to 50 Locations
8. Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team
9. IntelliCell BioSciences Expands Management Team
10. Questcor Pharmaceuticals Expands Repurchase Program
11. CuraLase Expands with New Franchise in Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... DIEGO, Feb. 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ... ended December 31, 2015. --> ... a net loss of $29.3 million, or $0.34 loss per share, ... per share for the same period in 2014. For the year ... $88.9 million, or $1.05 loss per share, as compared to a ...
(Date:2/11/2016)... , Germany and ... QGEN ; Frankfurt Prime Standard: QIA) today ... Targeted RNA Panels for gene expression profiling, expanding QIAGEN,s ... (NGS). The panels enable researchers to select from over ... changes and discover interactions between genes, cellular phenotypes and ...
(Date:2/11/2016)... 2016  Spectra BioPharma Selling Solutions (Spectra) is ... biopharma companies the experience, expertise, operational delivery and ... sales teams. Created in concert with industry leading ... strategic and tactical needs of its clients by ... both personal and non-personal promotion. ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... dedicated to delivering cutting-edge information focused on the development and manufacture of ... become a premier sponsor of the 2016 BioProcess International Awards – Recognizing ...
Breaking Biology Technology:
(Date:1/25/2016)... SEATTLE , Jan. 25, 2016  Glencoe Software, ... biotech, pharma and publication industries, will provide the data ... Phenotypic Screening Centre (NPSC). ... Phenotypic analysis ... even whole organisms, allowing comparisons between states such as ...
(Date:1/20/2016)... Minn. , Jan. 20, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... 2015. MedNet,s significant achievements are the result of the ... iMedNet eClinical , it,s comprehensive, easy-to-use ... --> --> Key MedNet growth achievements ...
(Date:1/13/2016)... , January 13, 2016 ... the addition of the  "India Biometrics ... & Forecast (2015-2020)"  report to ... ) has announced the addition of ... Market - Estimation & Forecast (2015-2020)" ...
Breaking Biology News(10 mins):